Pomalidomide is an oral immunomodulatory drug with antitumoral efficacy against relapsed or refractory multiple myeloma. It binds moderately (16%-42%) to plasma proteins.1 It is mainly eliminated by cytochrome-mediated hydroxylation in the liver.2 Its high plasma free fraction and low molecular weight (273g/mol) make it susceptible to glomerular filtration. Despite that,